LobbyingKyverna Therapeutics lobbying by quarter
Kyverna Therapeutics KYTX's latest lobbying report covers Q2 2026, at $120K. The four quarters Q4 2025–Q3 2026 total $250K. Its first report covers Q4 2025; the issues it reports most are Health Issues and Pharmacy.
Kyverna TherapeuticsKYTX
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $250K
- Last 4 quarters
- vs last quarter
- −100.0%
- Q3 2026 against the quarter before
- First report
- Q4 2025
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2025 | $50K | 1 |
| Q1 2026 | $80K | 2 |
| Q2 2026 | $120K | 2 |
| Q3 2026 | $0 | 0 |
By issue
- Health issues$170K · 3 reports
- Pharmacy$80K · 2 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- HOUSE OF REPRESENTATIVES3 reports
- SENATE3 reports
- Food & Drug Administration (FDA)1 reports
- Health & Human Services, Dept of (HHS)1 reports
- Office of Management & Budget (OMB)1 reports
- White House Office1 reports
Firms it paid
| Firm | ||
|---|---|---|
| Akin Gump Strauss Hauer & Feld | $170K | 3 quarters |
| Brownstein Hyatt Farber Schreck | $80K | 2 quarters |
Former officials lobbying for it
No lobbyist with a covered position.
Lobbying reports
| Filed by | ||
|---|---|---|
| 07/20for Q2 | Akin Gump Strauss Hauer & Feld | $60K |
| 07/17for Q2 | Brownstein Hyatt Farber Schreck | $60K |
| 04/20for Q1 | Akin Gump Strauss Hauer & Feld | $60K |
| 04/19for Q1 | Brownstein Hyatt Farber Schreck | $20K |
| 04/03for Q1 | Brownstein Hyatt Farber Schreck | Under $5,000 |
| 01/20for Q4 2025 | Akin Gump Strauss Hauer & Feld | $50K |
| 25/10/23for Q4 2025 | Akin Gump Strauss Hauer & Feld | Under $5,000 |